Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.23.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash Flows From Operating Activities:    
Net loss $ (13,619,884) $ (10,291,713)
Adjustments to reconcile net loss to net cash used in operating activities:    
Bad debt expense 7,000 22,698
Impairment loss on intangible assets 2,626,974  
Impairment loss on property and equipment 49,948  
Impairment loss on goodwill 463,000  
Depreciation and amortization 330,993 452,136
Change in fair value of contingent consideration (613,000)  
Common stock 982,647 700,652
Options 8,840 23,390
Changes in operating assets and liabilities:    
Accounts receivable 2,148,875 (940,477)
Other receivable 505,996 3,955
Prepaid expenses and other current assets 507,500 73,491
Accounts payable - suppliers (1,170,763) 1,508,516
Accounts payable - trade 156,828 (447,242)
Accrued expenses and other current liabilities (1,617,375) 1,467,306
Deferred revenue (367,511) (247,504)
Net Cash Used In Operating Activities (9,599,932) (7,674,792)
Cash Flows From Investing Activities:    
Purchase of intangible assets   (1,133,072)
Purchase consideration of MediaCrossing   (500,000)
Purchase of property and equipment (16,549) (39,414)
Net Cash Used In Investing Activities (16,549) (1,672,486)
Cash Flows From Financing Activities:    
Proceeds from exercise of warrants [1]   9,787,149
Proceeds from exercise of options   8,361
Repayment of PPP loan (149,843) (177,347)
Repayment of financed director and officer insurance premiums (402,155) (145,050)
Net Cash (Used In) Provided By Financing Activities (551,998) 9,473,113
Net (Decrease) Increase In Cash and Cash Equivalents (10,168,479) 125,835
Cash and Cash Equivalents - Beginning of the Period 24,907,963 24,782,128
Cash and Cash Equivalents - End of the Period 14,739,484 24,907,963
Cash paid during the year for:    
Interest 7,291 7,912
Non-cash investing and financing activities:    
Shares of common stock issued in satisfaction of accrued issuable equity   507,044
Accrual of warrant exercise issuance costs   83,519
Shares issued as partial consideration for intangible asset (18,683) 532,000
Financing of insurance premiums $ 357,866 362,625
Contingent consideration   $ 613,000
[1] Includes gross proceeds of $10,169,027, less issuance costs of $381,878.